PMID- 32340579
OWN - NLM
STAT- MEDLINE
DCOM- 20210811
LR  - 20210811
IS  - 1545-3278 (Electronic)
IS  - 0732-0582 (Linking)
VI  - 38
DP  - 2020 Apr 26
TI  - 30 Years of Biotherapeutics Development-What Have We Learned?
PG  - 249-287
LID - 10.1146/annurev-immunol-101619-031510 [doi]
AB  - Since the birth of biotechnology, hundreds of biotherapeutics have been developed 
      and approved by the US Food and Drug Administration (FDA) for human use. These 
      novel medicines not only bring significant benefit to patients but also represent 
      precision tools to interrogate human disease biology. Accordingly, much has been 
      learned from the successes and failures of hundreds of high-quality clinical 
      trials. In this review, we discuss general and broadly applicable themes that 
      have emerged from this collective experience. We base our discussion on insights 
      gained from exploring some of the most important target classes, including 
      interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-alpha), IL-6, IL-12/23, IL-17, 
      IL-4/13, IL-5, immunoglobulin E (IgE), integrins and B cells. We also describe 
      current challenges and speculate about how emerging technological capabilities 
      may enable the discovery and development of the next generation of 
      biotherapeutics.
FAU - Ghilardi, Nico
AU  - Ghilardi N
AD  - Department of Immunology, Genentech, South San Francisco, California 94080, USA; 
      email: nico.ghilardi@gmail.com, pappu.rajita@gene.com, arron.joseph@gene.com.
FAU - Pappu, Rajita
AU  - Pappu R
AD  - Department of Immunology, Genentech, South San Francisco, California 94080, USA; 
      email: nico.ghilardi@gmail.com, pappu.rajita@gene.com, arron.joseph@gene.com.
FAU - Arron, Joseph R
AU  - Arron JR
AD  - Department of Immunology, Genentech, South San Francisco, California 94080, USA; 
      email: nico.ghilardi@gmail.com, pappu.rajita@gene.com, arron.joseph@gene.com.
FAU - Chan, Andrew C
AU  - Chan AC
AD  - Research-Biology, Genentech, South San Francisco, California 94080, USA; email: 
      acc@gene.com.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Annu Rev Immunol
JT  - Annual review of immunology
JID - 8309206
RN  - 0 (Biological Products)
SB  - IM
MH  - Animals
MH  - Biological Products/history/*pharmacology/*therapeutic use
MH  - *Biological Therapy/history/methods
MH  - Biotechnology/history/methods
MH  - Clinical Trials as Topic
MH  - *Drug Development/history
MH  - Drug Discovery/history/methods
MH  - Drug Evaluation, Preclinical
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
OTO - NOTNLM
OT  - autoimmunity
OT  - biotherapeutics
OT  - clinical trial
OT  - inflammation
EDAT- 2020/04/29 06:00
MHDA- 2021/08/12 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/08/12 06:00 [medline]
AID - 10.1146/annurev-immunol-101619-031510 [doi]
PST - ppublish
SO  - Annu Rev Immunol. 2020 Apr 26;38:249-287. doi: 
      10.1146/annurev-immunol-101619-031510.